Aglio

L'aglio ha numerose proprietà curative fra le quali c'è quella relativa agli effetti benefici per il cuore,per la sua azione vasodilatatrice riduce naturalmente la pressione sanguigna e protegge da patologie cardiovascolari. I benefici dell'aglio sono legati ad una sostanza, il solfuro d'idrogeno (H2S). Sebbene non si

conoscono ancora i meccanismi molecolari che hanno a che fare con i processi di blocco del danno ossidativo a livello cellulare, si è constatato che il solfuro d'idrogeno rilassa i vasi e permette al sangue di fluire più facilmente.Inoltre, numerose ricerche hanno dimostrato che la pianta è utile anche nel rallentare la progressione dei tumori e nella cura di altre patologie.

Conclusioni

La cardiotossicità da farmaci rappresenta una grande limitazione per varie

strategie terapeutiche.Evidenti sono le varie patologie a livello del miocardio che possono insorgere in seguito a vari trattamenti farmacologici.Varie strategie cardioprotettive sono state adottate specialmente per quanto riguarda la classe dei farmaci antitumorali.La cardiotossicità da farmaci non è riconducibile

propriamente ad una specifica struttura molecolare,varie classi di farmaci agiscono con meccanismi molecolare propri,creando la tossicità a livello miocardico.Nell'ambito clinico è di fondamentale importanza la prevenzione a tale tossicità dal momento che non esistono precise cure

cardioprottetive.Operatori sanitari,infermieri,medici si occupano di affiancare alle cure farmacologiche un piano di prevenzione della cardiotossicità,che vada a valutare nel paziente ogni rischio cardiaco derivato da tali cure.Nella terapia antitumorale utilizzazioni di antracicline liposomiali,o agenti cardioprotettori come il Dexrazoxano hanno permesso di diminuire la cardiotossicità di questa classe di farmaci.Le principali strategie convenzionali di prevenzione al danno cardiaco sono l'elettrocardiogramma,l'ecocardiogramma,la risonanza magnetica cardiaca.Una valida alternativa diagnostica è sicuramente la valutazione dei marcatori biochimici di danno miocardico e di disfunzione

ventricolare,fondamentali nel riconoscimento precoce della cardiotossicità da chemioterapici.

Bibliografia

[1]Glauco Ambrosi.Anatomia dell'uomo.Edi Ermes.2006

[2] Robert M. Berne,Matthew N. Levy,Principi di fisiologia,terza edizione,casa editrice Ambrosiana,Milano,2002

[3]Klaassen C.D.,Watkins J.B.Elementi di tossicologia.Casarett & Doull.Ed.Ambrosiana,Milano,2013 pag.247

[4]Speight T.M.,Holford N.H.G.Farmacologia e terapia di Avery.Zanichelli Ed.Bologna,2004.Pag 893.895.

[5] Dapro B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes.Eur Heart J 2001;3(suppl K):K70-80

[6]Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774-82.

[7]Perrault LP, Denault AY, Carrier M, Cartier R, Belisle S.Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery. Can J Anaesth.2000; 47: 251-4. [8]Antzelevitch C, Sicouri S. Clinical relevance of cardiac arrhythmias generated by

afterdepolarisation: role of M cells in the generation of U wave, triggered activity, and torsades de pointes.J Am Coll Cardiol 1994;23:259–77.

[9]Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence.Circulation.1996;93:407-411.

[10]Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN.Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther 2006; 316:1098-106.

[11] Roden DM.Acquired long QT syndromes and the risk of proarrhythmia.J Cardiovasc Electrophysiol 2000;11:938-40

[12]Moss AJ, Robinson JL. The long QT syndrome: genetic consideration.Trends Cardiovasc Med 1992;2:81–3.

[13] Schwartz PJ,Periti M,Malliani A. The long QT syndrome.Am Heart J 1975;89:378-90 [14] Schwartz PJ, Crotti L,Insolia R. Arrhythmogenic disorders of genetic origin:long QT syndrome:from Genetics to management.Circ Arrhythm Electrophysiol 2012;in press.

[15]Menuck M, Voineskos G. Rapid parenteral treatment of acute psychosis. Compr Psychiatry 1981; 22: 351-61.

[16] Zareba W, Lin DA. Antipsychotic drugs and QT interval prolongation. Psychiatr Q Fall 2003; 74: 291-306.

[17]Haas SJ, Hill R, Krum H, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007;30:47-57.

[18]Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 2005;25:32-41.

[19] van Noord C, Straus SM, Sturkenboom MC, et al. Psychotropic drugs associated with corrected QT interval prolongation.J Clin Psychopharmacol 2009;29:9-15.

[20]Letsas K, Korantzopoulos P, Pappas L, et al. QT interval prolongation associated with venlafaxine administration. Int J Cardiol 2006;109:116-7.

[21]Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes. Sala M, Coppa F, Cappucciati C, Brambilla P, d'Allio G, Caverzasi E, Barale F, De Ferrari GM. Curr Opin Investig Drugs. 2006 Mar;7(3):256-63. Review.

[22]Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM (2012) Azithromycin and the risk of cardiovascular death. N Engl J Med 366: 1881-1890.

[23]Volberg WA, Koci BJ, Su W, et al. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther.

2002;302:320-327.

[24]Justo D, Zeltser D (2006) Torsades de pointes induced by antibiotics. Eur J Intern Med 17: 254-259.

[25] Nattel s,Ranger S,Talajic M,Lemery R,Roy d.Erythromycin induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism.Am J Med 1990;89:235-38

[26]Schoenenberger RA,Haefeli WE,Weiss p,Ritz R F.Association of erythromycin and potential fatal ventricular

tachycardia with Q-T prolungation (torsades de pointes).BMJ 1990;300:1375-76 [27]Mathews DR,Mcnutt B,Okerholm R,Flicker M,McBride G. JAMA.1991 nov 6;266(17);2375-6.

[28]Kohn K.K.Rim M.s:Yoon J. And Kim S.S.Torsade de pointes induced by terfenadine in a patient with long QT syndrome,Journal of Electrocardiology,27(4)343-346(1994).

[29]Sakemi H. and Van Natta B.Torsade de pointes induced by astemizole in a patient with prolongation of the QT interval,American Heart Journal,125,1436-1438(1993)

[30]De Abajo FJ and Rodriguez LAG. Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs.Br J Clin Pharmacol 1999;47:307-13.

[31]David Rampe,Marie Louise Roy,Adrienne Dennis,Arthur M Brown.A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.Febs letters Volume 417,issue1,3 November 1997,Pages 28-32. [32]Vitola J. Vukanovic J.and Roden D.M.Cisapride induced torsade de pointes.Journal of Cardiovascular Electrophysiology,9(10),1109-1113(1998)

[33]Piquetee R.K.Torsade de pointes induced by cisapride/clarythromycin interaction,Annals of Pharmacotherapy,33(1),22-26(1999)

[34]Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.

[35]Psaty B.M. And Furberg C.D.Rosiglitazone and cardiovascular risk,New England Journal of Medicine,356,2522-2524(2007).

[36]Fitzgerald GA, Patrono C. The Coxibs, selective inhibitors of Cyclooxygenase-2. New Engl J Med 2001; 345: 433-42 fans

[37]Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4-15 [38]Cannon CP, Curtis SP, Fitzgerald GA, Krum H, Kaur A, Bolognese JA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368: 1771-81

[39]Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. New Engl J Med 2005; 353: 2373-83

[40]Micheli A, Mugno E, Krogh V, et al, for the EUROPREVAL Working Group. Cancer prevalence in European registry areas.Ann Oncol 2002; 13: 840-65.

[41]Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship– Genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006; 98: 15-25.

[42]Kakavas PW,Ghalie R,Parrillo JE,Kaizer H,Barron JT.Angiotensin converting enzyme inhibitors in bone marrow transplant recipients with depressed left ventricular function.Bone Marrow Transplant 1995;15:859-61.

[43]Perez EA,Rodeheffer R.Clinical cardiac tolerability of trastuzumab.J Clin Oncol 2004;22:322-9.

[44]Pai VB,Nahata MC.Cardiotoxicity of chemotherapeutic agents:incidence,treatment andr prevention.Drug Saf 2000;22:263-302.

[45]Singal PK Iliskovic N.Doxorubicin-induced cardiomyopathy.N Engl J Med 1998;339:900- 5.

[46]Lipshultz SE,Lipsitz SR,Mone SM,et al.Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.N Engl J Med 1995;332:1738- 43.

[47]B.G. Katsung, ”Farmacologia generale e clinica”, IV Edizione Italiana, Piccin Nuova libraria, S.p.A., Padova, 2000, 55, 950.

[48]Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56:185-229.

[49] Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity Ann Intern Med 1996; 125:47-58.

identify strategies for cardioprotection?Prog Cardiovasc Dis 2010; 53:105-13. [51]Yeh ET,Bickford CL.Cardiovascular complications of cancer

therapy:incidence,pathogenesis,diagnosis,and management.J Am Coll Cardiol 2009;53:2231-47. [52]Menna P, Salvatorelli E, Minotti G. Cardiotoxicity of antitumor drugs.Chem Res Toxicol 2008; 21:978-989.

[53]Mavinkurve-Groothuis AM, Marcus KA, Pourier M, et al. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study. Eur Heart J Cardiovasc Imaging 2013 14:562-9.

[54]16. D rafts BC, Twomley KM, D’Agostino R Jr, et al. Low to Moderate Dose

Anthracycline-Based Chemotherapy Is Associated With Early Noninvasive Imaging Evidence of Subclinical Cardiovascular Disease. JACC Cardiovasc Imaging 2013 doi:pii: S1936- 878X(13)00259-3. 10.1016/j.jcmg.2012.11.017.

[55]Meinardi MT,van der Graaf WTA,van Veldhuisen DJ,Gietema JA,de Vries EG,Sleijfer DT.Detection of anthracycline-induced cardiotoxicity.Cancer Treat Rev 1999;25:237-47.

[56] G iordano SH, Lin YL, Kuo YF, et al. Decline in the use of anthracyclines for breast cancer. J Clin Oncol 2012; 30:2232-2239.

[57]Young AM, Dhillon T, Bower M. Cardiotoxicity after liposomal anthracyclines. Lancet Oncol 2004; 5:654.

[58]Yildirim Y, Gultekin E, Avci ME, et al. Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal cancer. Int J Gynecol Cancer 2008;18:223.

[59]Berry G, Billingham M, Alderman E, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicin.Ann Oncol 1998; 9:711.

[60]Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (Doxil):reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000;11:1029.

[61]Spallarossa P, Garibaldi S, Altieri P, et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in

cardiomyocytes in vitro. J Mol Cell Cardiol 2004; 37:837-846.

[62]Wiseman LR, Spencer CM: Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs 1998; 56: 385-403.

[63]Lipshultz SE,Scully RE,Lipsitz SR,et al.Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with-risk acute Lymphoblastic leukaemia:long-term follow-up of a prospective,randomised trail.Lancet Oncol 2010;11:950-61

[64]Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997; 15:1318-1332.

[65]Walker JR,Sharma A,Lytwyn M,et al.The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity.J Am Soc Echocardiogr 2011;24:699- 705

[66]Tikoo K,Sane MS,Gupta C.Tannic acid ameliorates doxorubicin-induced cardiotoxicity and potentiates its anti-cancer activity:potential role of tannins in cancer chemotherapy.Toxicol Appl Pharmacol 2011;251:191-200.

[67]Van Dalen EC,van der Pal HJ,Bakker PJ,Caron HN,Kremer LC.Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children:a systematic review.Eur cancer 2004;40:643-52.

[68]Goldberg MA,Antin JH,Guinan EC,Rappeport JM.Cyclophosphamide cardiotoxicity:an analysis of dosing as a risk factor.Blood 1986;68:1114-8

[69]Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.

[70] Perez EA. Paclitaxel and cardiotoxicity. J Clin Oncol 1998; 16: 3481-3482. [71]Keefe DL.Trastuzumab-associated cardiotoxicity.Cancer 2002;95:1592-600

[72]Martin M,Esteva FJ,Alba E,et al.Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.Oncologist 2009;14:1-11. [73]Sengupta PP,Northfelt DW,Gentile F,et al.Trastuzumab-induced cardiotoxicity:heart failure at the crossroads.Mayo Clin Proc 2008;83:197-203.

[74]Ewer MS,Vooletich MT,Durand JB,et al.Reversibility of trastuzumab-related

cardiotoxicity:new insights based on clinical course and response to medical treatment.J Clin Oncol 2005;23:820-7826.

[75]De Azambuja E, Bedard PL, Suter T, et al. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol 2009;4:77–88.

[76] Lenihan D, Suter T, Brammer M, et al. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol 2012;23:791-800.

[77]Fedele F, Riccio G, Coppola C, et al. Comparison of cardiotoxic effects of different ErbB2 inhibitors. Breast Cancer Res Treat 2012;133:511-21.

[78]Ewer M, Lippman S. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005;23:2900–2902.

[79]Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related

cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820–7826.

[80]Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center Experience. J Clin Oncol 2006;24:4107–4115.

[82]Youssef G,Links M. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer.Am J Cardiovasc Drugs 2005;5:233-43.

[83]Schwartz RG,McKenzie WB,Alexander J,et al.Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy.Seven-year experience using serial radionuclide angiocardiography.Am J Med 1987;82:1109-18.

[84]Bono P, Elfving H, Utriainen T, et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 2009;20:393-394.

[85]Cobleigh MA, Langmuir VK, Sledge GW et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.Semin Oncol 2003; 30: 117-124. [86]Hawkes EA,Okines AF,Plummer C,Cunningham D.Cardiotoxicity in patients treated with bevacizumab is potentially reversible.J Clin Oncol 2011;29:e560-2.

[87]Zielinski S: FDA, Genentech warn of heart problems with bevacizumab. J Natl Cancer Inst 2004; 96: 1353-1360.

[88] Kerkela R, Grazette L, Yakobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006; 12: 908-916.

[89]Chen MH,Kerkela R,Force T.Mechanism of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics.Circulation 2008;118:84-95.

[90]Chu TF,Rupnick MA,Kerkela R,et al.Cardiotoxicity associated with the tyrosine kinase inhibitor sunitinib.Lancet 2007;370:2011-9.

[91ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifene, alone or in

conbination) trial after completion of 5 years’ adjuvant treatment for breast cance. Lancet 2005; 365: 60-62.

[92] Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy fpr early breast cancer on recurrence and 15-year survival: an overview of the

randomised trial. Lancet 2005; 365: 1687-1717.

[93] Bailar JC III, Byar D. Estrogen treatment for cancer of the prostate.Cancer 1970; 26: 257- 261.

[94]Floyd JD, Nguyen DT, Lobins RL et al. Cardiotoxicity of cancer therapy.J Clin Oncol 2005; 23: 7685-7696.

[95]Adams MJ, Lipshultz SE, Schwartz C et al. Radiation-associated cardiovascular disease: manifestations and management. Semin Radiat Oncol 2003; 13: 346-356.

[96]Lee PJ, Mallik R: Cardiavascular effect of radiation therapy: Practical approach to radiation therapy-induced heart disease, Cardiol Rev 2005; 13:346-356.

[97]Perez CA, Brady LW (eds). Principles and practice of radiation oncology (4th ed). Philadelphia PA: Lippincott, Williams & Wilkins, 2004.

breast cancer who participated in trials of radiotherapy.J Clin Oncol 1994; 12: 447-453.

[99]Eidem BW.Identification of anthracycline cardiotoxicity:left ventricular ejection fraction is not enough.J Am Soc Echocardiogr 2008;21:1290-2.

[100]Marchandise B,Schroeder E,Bosly A,et al.Early detection of doxorubin

cardiotoxicity:interest of Doppler echocardiographic analysis of left ventricular filling dynamics.Am Heart J 1989;118:92-8.

[101]Geyer H, Caracciolo G, Abe H, et al. Assessment of myocardial mechanics using speckle tracking echocardiography: fundamentals and clinical applications. J Am Soc Echocardiogr 2010;23:351-69.

[102]Wassmuth R,Lentzsch S,Erdbruegger U,et al.Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study.Am Heart J 2001;141:1007-13.

[103]Morandi P,Ruffini PA,Benvenuto GM,Raimondi R,Fosser V.Cardiac toxicity of high-dose chemotherapy.Bone Marrow Transplant 2005;35:323-34.

[104]Herman EH,Lipshultz SE,Rifai N,et al.Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity.Cancer Res 1998;58:195-7.

[105]Koh E,Nakamura T,Takahashi H.Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats.Circ J 2004;68:163-7.

[106]Cardinale D,Sandri MT.Role of biomarkers in chemotherapy-induced cardiotoxicity.Prog Cardiovasc Dis 2010;53:121-9.

[107]Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy- induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114:2474-2481.

[108]Soker M,Kervancioglu M.Plasma concentrations of NT-pro-BNP and cardiac troponin I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood

malignancy.Saudi Med J 2005;26:1197-202.

[109]Chen S,Garami M,Gardner DG.Doxorubicin selectively inhibits brain versus atrial natriuretic peptide gene expression in cultured neonatal rat myocytes.Hypertension 1999;34:1223-31.

[110]Hamed S,Barshack I,Luboshits G,et al.Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy.Eur Heart J 2006;27:1876-83.

[111]Neilan TG,Jassal DS,Scully MS,et al.Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression.Eur Heart J 2006;27:1251- 6.

[112]Hollman PC and Katan Mb.Bioavailabity and health effects of dietary flavonols in man.Arch Toxicol Suppl 20:237-48,1998.